SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial...
Les résultats de la 4e analyse intermédiaire réalisée dans le cadre de l’étude PEARL sur la prévention de la migraine en situation réelle ont...
Vierte Zwischenanalyse der PEARL-Studie zur Migräneprävention wird auf dem 10. Kongress des European Association of Neurology (EAN) in Helsinki...
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the...
Generic Victoza® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market. This launch...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.